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We disagree with the Cochrane Schizophrenia Group’s (CSzG) self-assessment that the problems we 
identified in their reviews of popular antipsychotics for schizophrenia are not serious. We encourage 
people to read our 2012 (1) paper where we document the problems in great detail and their likely 
impact on estimates of efficacy. We have not examined their impact on estimates of adverse effects, 
but we invite readers to do so. 
 
We reject Professor Adam’s claim that the CSzG was not forewarned that there were serious problems 
with their review of cognitive behavioural therapy for psychosis (2). In a meeting with the CSzG 
Editors in 2012, one of us (Paul Hutton) called for both it and their review of risperidone (3) to be 
retracted, fixed and then re-issued. Despite assurances that our concerns would be followed up, we 
have received no correspondence since then. Both these reviews contain multiple errors which greatly 
undermine their negative conclusions, yet both have been allowed to continue to influence public 
policy and debate. 
 
As discussed at the 2012 meeting, we believe the CSzG system for documenting and responding to 
constructive criticism and feedback is neither transparent nor effective. Until there is evidence of 
improved responsiveness, we encourage readers to submit their critical feedback to independent and 
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